AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $229.32, giving the company a market capitalization of 405.48B. It carries a P/E multiple of 96.76 and pays a dividend yield of 2.9%.
As of 2026-02-25, AbbVie(ABBV) stock has fluctuated between $228.24 and $232.54. The current price stands at $229.32, placing the stock +0.5% above today's low and -1.4% off the high.
The AbbVie(ABBV)'s current trading volume is 1.92M, compared to an average daily volume of 6.65M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
RBC Capital analyst Trung Huynh initiated coverage of AbbVie (ABBV) with an Outperform rating and $260 price target The shares have underperformed on concerns A...
Key Points AbbVie has a collection of drugs that produce substantial cash flow. The company has steadily rewarded investors with dividend growth. 10 stocks w...
AbbVie (NYSE:ABBV) received FDA approval for its all oral, fixed duration VENCLEXTA and acalabrutinib regimen for previously untreated chronic lymphocytic leuke...
Analyst ratings
64%
of 33 ratingsMore ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has started a new Phase 1 trial called “A Phase 1 Pharmacokinetic Study in Hea...
AbbVie (ABBV) announced a new $380M investment to build two new active pharmaceutical ingredient manufacturing facilities at its current North Chicago, Illinois...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a mid-stage trial to test new drugs for idiopathic pulmonary fibros...
This week's dividend activity included increased payouts from Sherwin-Williams (SHW) and Analog Devices (ADI) as well as declarations from companies such as Hal...
Advertisement Why AbbVie’s latest earnings are back in focus AbbVie (ABBV) is back on many investors’ watchlists after reporting strong fourth quarter and ful...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.